Naia Pharmaceuticals Overview
Naia Pharmaceuticals General Information
Description
Operator of a biopharmaceutical company created to develop drugs for Short Bowel Syndrome. The company develops clinically advance drug candidates for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases enabling health care providers to treat gastrointestinal problems and disorders and reduce recovery times.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Naia Pharmaceuticals Valuation & Funding
| Deal Type |
Date |
Amount |
Valuation/
EBITDA |
Post-Val |
Status |
Debt |
This information is available in the PitchBook Platform. To explore Naia Pharmaceuticals‘s full profile, request access.
Request a free trial
Naia Pharmaceuticals Competitors (1)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| 00000000 000000000 |
Corporation |
Melbourne, Australia |
00 |
|
000000&0 |
|
Naia Pharmaceuticals Executive Team (5)
| Name |
Title |
Board Seat |
Contact Info |
| Mark Bagnall |
Co-Founder, Board Member, Chief Operating Officer & Chief Financial Officer |
|
|
| Sherine Helmy |
Co-Founder & Board Member |
|
|
| H. Daniel Perez MD |
Co-Founder, Chairman & Chief Executive Officer |
|
|
2 Former Executives
Naia Pharmaceuticals Board Members (4)
| Name |
Representing |
Role |
Since |
| 0000 00 |
Naia Pharmaceuticals |
Board Member |
000 0000
|
| 0000 000000 00.0 |
Self |
Board Member |
000 0000
|
| 000000 0000000000 000 |
Self |
Board Member |
000 0000
|
| 0000000 00000 |
Naia Pharmaceuticals |
Co-Founder & Board Member |
000 0000
|
Naia Pharmaceuticals Former Investors
| Investor Name |
Investor Type |
Holding |
Investor Since |
Participating Rounds |
Contact Info |
This information is available in the PitchBook Platform. To explore Naia Pharmaceuticals‘s full profile, request access.
Request a free trial